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Aim Cross-sectional studies reported associations between short leucocyte telomere length (LTL) and measures of vascular
and cardiac damage. However, the contribution of LTL dynamics to the age-related process of cardiovascular (CV) re-
modelling remains unknown. In this study, we explored whether the rate of LTL shortening can predict CV phenotypes
over 10-year follow-up and the influence of established CV risk factors on this relationship.
Methods and
results
All the participants from the MRC National Survey of Health and Development (NSHD) with measures of LTL and trad-
itional CV risk factors at 53 and 60–64 years and common carotid intima-media thickness (cIMT), cardiac mass and left
ventricular function at 60–64 years were included. LTL was measured by real-time polymerase chain reaction and avail-
able at both time points in 1033 individuals. While LTL at53 years was not linked with any CV phenotype at60–64 years, a
negative association was found between LTL and cIMT at 60–64 years (b ¼ 20.017, P ¼ 0.015). However, the strongest
association was found between rate of telomere shortening between 53 and 60–64 years and values of cIMT at 60–64
years (b ¼ 20.020, P ¼ 0.006). This association was not affected by adjustment for traditional CV risk factors. Cardiac
measurements were not associated with cross-sectional or longitudinal measures of LTL.
Conclusion These findings suggest that the rate of progression of cellular ageing in late midlife (reflected by the rate of LTL attrition)
relates to vascular damage, independently from contribution of CV risk factor exposure.
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Translational Perspective
This is the first report to analyse the relationship between a marker of cellular ageing (LTL) and a full range of subclinical measures of cardio-
vascular disease. We found an association between the dynamic change of LTL and subclinical measures of atherosclerosis. This association
remained significant following multiple adjustments for cardiovascular risk factors, behavioural, and socio-economic factors. In contrast, no
associations were found with the cardiac phenotype. Our results support the hypothesis that biological pathways regulating cellular ageing can
influence the evolution of cardiovascular disease in humans.
Introduction
Telomeres are multiple repetitions of standard DNA sequences
(TTAGGG)n, which cap the ends of eukaryotic chromosomes and
protect them from aberration and fusion.1 As DNA polymerase
cannot fully replicate the 3′ end of linear DNA, somatic cell replica-
tion results in aprogressive loss of telomeres repeats, a process even-
tually resulting in cellular senescence or apoptosis.2 The recent
availability of high throughput assays to measure telomere length
on peripheral leucocytes (leucocyte telomere length, LTL) has
allowed investigation into the role of telomere length biology in the
evolution of cardiovascular (CV) disease. This has led to several ob-
servational studies reporting cross-sectional associations between
LTL, levels of CV risk factors3 and clinical4 or subclinical5 measures
of CV damage. Consequently, LTL has been suggested as a novel
marker of CV ageing, integrating the cumulative lifetime burden of
genetic factors and environmental stressors involved in the evolution
of CV damage. It remains unknown, however, whether CV pheno-
types in mid and later life are influenced by the dynamic change of
LTL, and whether any such associations are independent of tradition-
al CV risk factors.
The MRC National Survey of Health and Development (NSHD,
also known as the 1946 British Birth Cohort) is the oldest of the
British Birth Cohort studies,6 and is unique in providing measures
of LTL and CV risk factors at the ages of 53 and 60–64 years, together
with a characterization of the cardiac and vascular phenotypes at the
later time point. The aim of this study was to determine whether the
rate of LTL shortening over 10 years predicts cardiac and vascular
phenotypes independent of established CV risk factors.
Methods
Population and cardiovascular risk factors
assessment
The MRC NSHD is a social class stratified sample of all singleton births to
married parents in England, Scotland, and Wales during 1 week in March
1946. LTL measures were available in 1033 participants at both 53- and
64-year follow-up visits. The 53-year visit was performed at home by a
team of trained nurses while at 60–64 year participants were invited to
attend one of six clinical research facilities (CRFs) across Britain or, if
they were unable or unwilling to travel, to have a research nurse visit
them at home.7 More details on the assessment of CV risk factors are
reported in the Supplementary material online. Ethical approval for the
study was obtained from the Greater Manchester Local Research
Ethics Committee and the Scotland A Research Ethics Committee for
the 60–64 years collection and from the Multicentre Research Ethics
Committee for the 53 years collection. Written, informed consent was
obtained from the study member for each component of each data
collection.
Leucocyte telomere length assay
At bothages, DNAwasextracted from frozenEDTAbloodsamplesusing
Puregene DNA isolation kits (Flowgen, Leicestershire, UK).8 LTL at both
ages was measured in the same laboratory according to a previously vali-
dated real-time polymerase chain reaction technique in a blinded
fashion.9 More details on the method used to measure LTL are reported
in the Supplementary material online.
Vascular phenotype
The right and left common carotid arteries (cIMT) were imaged longitu-
dinally, 1 cm proximal to the carotid bifurcation following a standardized
protocol.10 All measures were undertaken using an ultrasound scanner
(Vivid I or Vivid 7, GE Healthcare) with a high-resolution probe
(12 MHz). More details on the methods used for image acquisition and
analysis are reported in the Supplementary material online.
Cardiac phenotype
Echocardiography was performed by a trained, experienced sonogra-
pher using GE Vivid I machines. Echocardiographic images were obtained
from parasternal long-axis and short-axis, apical five-chamber, four-
chamber, three-chamber, two-chamber and aortic views along with con-
ventional and tissue Doppler in the four-chamber view. Image analysis,
including wall and chamber measurements for the evaluation of left ven-
tricular mass, ejection fraction, and diastolic function, was undertaken in
a single core laboratory according to ASE/EAE guidelines11 by three
experienced readers blinded to patient identity using the GE EchoPac
software (GE CT, USA). The left ventricular mass (LVM) was indexed
to the body surface area (LVM/BSA).
Quality assurance of echocardiography was performed throughout
the study and blind duplicate reading reproducibility studies were
carried out to establish inter- and intra-reader reliability. These
showed excellent reproducibility (intra-class correlation coefficients
were .0.9).
Statistical analysis
Linear regression models were used to investigate the unadjusted asso-
ciation between LTL at 53 years, LTL at 60–64 years and their difference
with each measure of vascular (cIMT) and cardiac phenotype at 60–64
years. A series of multiple regression models were then fitted to
examine whether the traditional CV risk factors and other potential con-
founders influenced any associations observed between LTL and the
vascular and cardiac phenotypes. More details on the statistical
methods are reported in the Supplementary material online.
Results
Descriptive statistics
Characteristics of the study population at both time points are shown
in Table 1. Not all individuals with LTL at 53 years had a measure of
LTL at 60–64 years. However, the characteristics at age 53 years of
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the groups with and without an LTL measure at 60–64 years were
similar. Overall, the population was overweight with relatively high
levels of systolic blood pressure and tendency to high levels of chol-
esterol and HbA1c. However, values of cIMT and cardiac measures
were consistent with a relatively healthy population with largely
normal left ventricular systolic and diastolic function, normal cIMT,
and normal cardiac structure. Table 1S (Supplementary material
online) shows the characteristics of the population based on tertiles
of LTL changes. Only HDL-cholesterol varied significantly across the
categories of rate of change in LTL.
Associations between leucocyte telomere
length at 53 and 60–64 years and
cardiovascular phenotypes
LTL at 53 years was not associated with vascular (cIMT) measures at
60–64 years (Figure 1A). Similarly, there was no evidence of associa-
tions between LTL at 53 years and any of the cardiac phenotypes at
60–64 years old (Supplementary material online, Table S1).
At the age of 60–64 years, LTL was inversely associated with cIMT
[regression coefficient (b) ¼ 20.017 mm per 1 standard deviation
(SD) LTL; 95% confidence interval (CI): 20.031, 20.003; P ¼
0.015; R2 ¼ 0.005] (Figure 1B and Supplementary material online,
Table S2). The association was greatly attenuated in the adjusted
model (Model 2) (total cholesterol, systolic blood pressure at age
60–64, socio-economic status, medications use, clinic centre, and
past history of myocardial infarction) (b ¼ 20.008; 95% CI:
20.023, 0.006; P ¼ 0.257; R2 ¼ 0.07). Addition of LTL measure at
60–64 years in the fully adjusted model (model 2) did not sub-
stantially increase the overall model fit (R2 change ¼ 0.005,
P ¼ 0.134). No associations were observed between LTL at 60–64
years and cardiac measurements (Supplementary material online,
Table S2).
Associations between longitudinal change
of leucocyte telomere length and
cardiovascular phenotypes
In 74% of participants, there was telomere shortening over the
follow-up (Figure 2). A greater decrease in LTL change between the
ages of 53 and 60–64 years was associated with thicker cIMT at
60–64 years old (unadjusted model: b ¼ 20.020 mm per 1 SD de-
crease in LTL; 95% CI: 20.027, 20.005; P ¼ 0.006; R2 ¼ 0.008)
(Table 2 and Figure2). The strengthof this association was not affected
by multiple adjustment (model 3: b ¼ 20.016, 95% CI: 20.029,
20.002; P ¼ 0.022; R2 ¼ 0.12) (Table 2). Addition of LTL change in
the fully adjusted model (model 3) only slightly increased the
overall model fit (R2 change ¼ 0.007, P ¼ 0.108). This association
was linear so that the association with cIMT was observed in indivi-
duals with telomere elongation and those with telomere shortening.
The right cIMT showed very similar findings, with the left showing a
somewhat weaker association (Table 2). No associations were
found between changes in LTL and cardiac phenotype measures of
left ventricular mass, ejection fraction, and diastolic function (data
not shown).
Similarly, a greater shortening of LTL was associated with higher
odds of increased cIMT [OR (95% CI) per one SD of LTL ¼ 1.83
(1.03–3.25); P ¼ 0.038]. Individuals diagnosed with carotid plaques
had higher shortening of LTL during the follow-up compared with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographic, anthropometric, and biochemical parameters
At 53 years
(n5 2611)
At 60–64 years
(n 5 1207)
At 53 years with LTL measures
at follow-up (n5 1033)
At 53 years without LTL measures
at follow-up (n 5 1602)
Gender, male (%) 1297 (49.7) – 488 (47.2) 809 (51.3)
BMI, kg/m2 27.34+ 4.65 27.93+ 4.88 27.20+ 4.46 24.40+ 4.47
Systolic BP, mmHg 136+ 20 137+ 8 136+ 20 136+ 20
Diastolic BP, mmHg 84+ 12 18+ 10 84+ 12 84+ 12
HbA1c, %a 5.63+ 0.69 5.81+ 0.71 5.61+ 0.57 5.70+ 0.76
Cholesterol, mmol/La 5.99+ 1.08 5.53+ 1.19 6.08+ 1.07 6.09+ 1.09
Triglycerides, mmol/La 1.78+ 1.49 1.16+ 0.78 2.08+ 1.42 2.16+ 1.53
HDL, mmol/La 1.59+ 0.48 1.54+ 0.41 1.67+ 0.47 1.66+ 0.49
cIMT, mm – 0.683+ 0.129 – –
R_cIMT, mm – 0.666+ 0.134 – –
L_cIMT, mm – 0.692+ 0.151 – –
Ejec. Fr., % – 68+ 10 – –
LA Dia., mm – 3.81+ 0.57 – –
LVM/BSA, g/m2 – 92.46+ 27.12 – –
E/A ratio – 0.97+ 0.27 – –
LTL (bp) 5646+ 1925 4285+ 1309 5553+ 1733 5555+ 1755
Values are presented as mean+ standard deviation.
aGeometric mean+ standard deviation or absolute number of participants and percentages (%).
cIMT, average carotid artery; R_cIMT, right carotid artery; L_cIMT, left carotid artery; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVM/BSA, left ventricular mass
indexed to body surface area; E/A ratio, ratio between early and late mitral inflow velocity.
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those without plaques (P, 0.01). Sensitivity analysis did not affect
the results.
Discussion
This is the first study, to our knowledge, to explore the association
between changes in LTL over 10 years and CV phenotypes. We
found, using data from a nationally representative cohort of 60–
64-year-old men and women, that a faster rate of decrease in LTL
over 10 years was associated with increased cIMT. This association
was seen in participants with both elongation and shortening of
LTL and persisted after adjustment for potential confounders and
mediators. Furthermore, single measures and longitudinal variations
of LTL were not related with cardiac phenotypes. These results
suggest that, over and above the contribution of classic CV risk
factor exposure, a small proportion of the variation in vascular
phenotype in late midlife relates to mechanisms regulating the rate
of cellular ageing.
Several studies have reported cross-sectional associations
between shorter LTL with subclinical and clinical markers of athero-
sclerosis.4,5 We have shown that the negative relationship between
LTL and cIMT described in previous studies is likely to be consequent
to a faster rate of LTL change during the lifespan. This suggests that,
either regulation of LTL dynamics has a role in the evolution of
vascular disease, or that the processes of cellular ageing and athero-
sclerosis are influenced by similar factors and proceed in parallel. A
Figure 1 Scatter plot of leucocyte telomere length (bp) measured at 53 years. (A) (R ¼ 0.031, P ¼ 0.271, n ¼ 1261) and at 60–64 years
(B) (R ¼ 20.075, P ¼ 0.046, n ¼ 717) against values of carotid intima-media thickness (mm) measured at 60–64 years. Spearman rank correlation
analyses were performed. The line represents the regression line for the unadjusted analysis.
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recent subanalysis of the Cardiovascular Health Study supports the
first hypothesis, suggesting a causal relationship between ageing path-
ways and risk of CV disease.12 The ability of LTL to directly influence
the evolution of vascular damage could lie on the unique feature of
LTL to mirror telomere dynamics in haematopoietic stem cells
(HSCs).13 As these cells also represent the haematological precur-
sors of endothelial progenitor cells, a faster rate of LTL shortening
may reflect a faster rate of telomere attrition in HSC reserves, ultim-
ately resulting in a limited ability of the bone marrow to supply an
adequate number of endothelial progenitor cells for effective repar-
ation of vascular damage.14 On the other hand, several studies have
supported the second hypothesis, suggesting oxidative stress as a po-
tential mediator of the association between shorter LTL and higher
levels of vascular damage. Oxidative stress exposure is currently con-
sidered the main driver of atherosclerosis.15 Similarly, an elevated
burden of oxidative stress may result in a faster rate of LTL attrition
by increasing the oxidative stress-mediated damage to the telomere
sequence.16– 18 Therefore, exposure to increased levels of oxidative
Figure2 Scatter plot of relative change in leucocyte telomere length (%) during the follow-up and values of carotid intima-media thickness at 60–
64 years. Relative change in LTL ¼ {[LTL (bp) at 60–64 years] – [LTL (bp) at 53 years]}/[LTL (bp) at 53 years] * 100. Values of carotid intima-media
thickness are unadjusted and the reference dashed line separates individuals with telomere elongation from those with telomere shortening during
the follow-up. Individuals with leucocyte telomere length shortening during the follow-up have increased values of carotid intima-media thickness at
60–64 years (R ¼ 20.10; P ¼ 0.01).
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Table 2 Mean difference (regression coefficient) of cardiovascular phenotypes per 1 SD higher change in leucocyte
telomere length (change conditional to baseline leucocyte telomere length)
cIMT (mm) R_cIMT (mm) L_cIMT (mm)
b (95% CI) P-value b (95% CI) P-value b (95% CI) P-value
Unadjusted 20.020 (20.027; 20.005) 0.006 20.019 (20.032; 20.006) 0.004 20.014 (20.027; 20.001) 0.033
Model 1 20.015 (20.026; 20.003) 0.011 20.019 (20.032; 20.006) 0.005 20.012 (20.025; 20.001) 0.068
Model 2 20.017 (20.030; 20.003) 0.007 20.018 (20.035; 20.005) 0.009 20.014 (20.029; 20.001) 0.074
Model 3 20.016 (20.029; 20.002) 0.022 20.017 (20.033; 20.003) 0.012 20.015 (20.030; 20.001) 0.052
LTL measures and all other confounders available in 672 participants at 53 and 64 years follow-up.
Generalized linear model; Model 1 ¼ age difference in years, gender, smoking status 99, difference in BMI (99–09); Model 2 ¼ Model 1+ cholesterol 2009, systolic BP 2009,
socio-economic status, anti-inflammatory use, OAC, lipid lowering, clinic centre and history of MI; Model 3 ¼ CVD risk SCORES (including age, gender, smoking, total- and
HDL-cholesterol, systolic blood pressure) based on the SCORE charts, difference in BMI (99–09), socio-economic status, anti-inflammatory use, OAC, lipid lowering and clinic
centre.
cIMT, average carotid artery; R_cIMT, right carotid artery; L_cIMT, left carotid artery.
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stress may explain the parallel evolution of vascular damage and telo-
mere attrition, potentially accounting for our findings.
Several studies have reported cross-sectional associations
between LTL and smoking, obesity, and levels of insulin resistance.3
Consequently, researchers have suggested an increased CV risk
factor burden could represent the primary mediator of the associ-
ation between LTL and vascular phenotype, leading to a faster rate
of LTL shortening and vascular remodelling. Although this hypothesis
cannot be excluded, the few investigations that have analysed the
determinants of LTL shortening in healthy and diseased populations
found limited or no influence of CV risk factors levels on the rate of
LTL attrition.19 –21 This evidence raised doubts on the ability of trad-
itional CV risk factors to effectively influence LTL dynamics and to
mediate its association with CV phenotypes. Our study demon-
strates that the association between LTL dynamics and markers of
CV disease is unlikely to be dependent on traditional CV risk factor
exposure, suggesting that other factors (such as oxidative stress or
genetic mechanisms regulating the progression of cellular ageing)
could drive this association.
Inconsistent associations have been reported between LTL and
LVM or left ventricular function.22– 24 We did not find associations
between single measures and longitudinal measures of LTL and
cardiac phenotypes. Our results are in line with current understand-
ing of the LTLbiologyand the processes regulating the mechanisms of
myocardial remodelling. Given that the haematopoietic system is the
most proliferative among human tissues, age-dependent telomere
shortening in HSCs, as expressed in LTL dynamics, is unlikely to
reflect the evolution of the ageing process of cells with slow turnover
rate, such as cardiomyocytes. Our findings support this hypothesis
and provide the first epidemiological evidence of a possible different
role of LTL biology in the evolution of cardiac and vascular remodel-
ling. In keeping with our results, previously reported data from a
meta-analysis including NSHD did not documented associations
between LTL and clinical measures of muscular ageing, such as per-
ipheral muscle strength.25
The MRC NSHD has a number of strengths for the investigation of
LTL biology and its relationship with CV risk factors and phenotypes.
Firstly, the10-yearfollow-upbetweenLTLmeasuresandtherelatively
large number of participants included in the analysis represents the
most important strengths. Indeed, the yearly rate of change of LTL
is extremely low when compared to the ability of current LTL
assays to detect small differences in telomere length.26 Consequent-
ly, changes in LTL over a long follow-up period and a large sample size
are necessary to detect inter-individual variations in telomere attri-
tion rates with confidence. Secondly, the acquisition of cIMT
images was performed according to current guidelines.10 Further-
more, the use of automated edge detection programme has
enabled a considerable reduction in differences between readers
and has minimized the risk of change in reading behaviour over
time (reader drift).27 The high interclass correlation between
readers and the presence of an average cIMT in keeping with refer-
ence values confirm the quality of our cIMT acquisition and analysis
protocols. While longitudinal studies have documented uncertain
utility of repeated cIMT measures for prediction of CV outcome, a
single measure of cIMT remains a useful tool to identify people at
higher CV risk.28 The utility of this measure is strongly influenced
by accuracy and standardization of the protocols for cIMT images
acquisition and analysis.27 Finally, the availability of data on a wide
range of established and novel CV risk factors and potential confoun-
ders atbothages,where LTLwasmeasuredallowed, for the first time,
investigation of the independent contribution of LTL dynamics to CV
phenotype.
Our report also has several limitations. The associations reported
in this study are observational, and therefore no definitive conclu-
sions can be made regarding causality. The proportion of cIMT vari-
ability explained by LTL dynamics is small and unlikely to be of clinical
relevance. However, the aim of this paper was not to improve CV
disease risk prediction by addition of a longitudinal measure of cellu-
lar ageing (such as LTL) to common CV risk factors, but to explore its
relationship with a measure of vascular remodelling (surrogate
outcome), to unravel possible new mechanisms of progression of
atherosclerosis (i.e. biological pathways regulating cellular ageing).
Furthermore, it should be highlighted that also the fully adjusted
model including the continuous variable of future CVD risk (calcu-
lated with the SCORE charts) explains only a small proportion of
the variability of cIMT in our population. This could be explained
by the fact that our cohort comprises mainly CVD-free participants
(as suggested by the normal average values of cIMT). Consequently,
if LTL marks the residual ability to repair the vascular damage, a rela-
tively low CV risk factor burden is likely to have underestimated the
possible contribution of LTL dynamics to the cIMT variability in our
analyses. Attrition is unavoidable in long-running studies such as
NSHD, but our previous analyses have shown that the samples at
53 and 60–64 years remained broadly representative of the British
born population of that age.29,30 Furthermore, we showed that the
characteristics at age 53 years of the groups with and without an
LTL measure at 60–64 years were similar and thus any drop out
between the two ages is likely to have had a minimal effect on our
findings. We did not measure telomere length in vascular cells but
only in leucocytes. This is likely to have weakened the association
between LTL dynamics and cIMT. However, Wilson et al.31 previous-
ly reported that LTL predicts vascular telomere length in humans
with and without vascular disease and a strong synchronization
between LTL and telomere length of other tissues was reported
also by other authors.13,32,33 We used measures of cardiac remodel-
ling that are strongly influenced by values of blood pressure. This
might have reduced our ability to detect associations between LTL
and cardiac phenotypes. However, our results raise further doubts
on the associations between LTL and LVM, previously reported in
cross-sectional studies.23,24 Finally, it is now well established that
the delicate balance between injurious and repairing factors deter-
mines the level of genomic instability in each individual as well as
his/her risk of developing age-related diseases, such as CV
disease.34 In our paper, we measured a marker of cellular ageing
which represents only one of the multiple pathways contributing to
genomic instability. Larger longitudinal studies will need to confirm
our results and address whether the combination of multiple
ageing markers can better define the role of cellular ageing in the
evolution of CV disease.
Conclusions
Our results suggest that previously reported cross-sectional associa-
tions between short LTL and measures of subclinical atherosclerosis
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are likely dependent upon a faster rate of LTL attrition. Importantly,
the association was only partially confounded by exposure to CV risk
factors. This suggests that, over and above chronological age and CV
risk factors, a small proportion of vascular but not cardiac remodel-
ling could be explained by mechanisms regulating the rate of progres-
sion of cellular ageing during lifespan.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Isolated left ventricular apical hypoplasia, characterized by cardiac magnetic
resonance imaging
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A 17-year old female presented with atypical
chest pain. Clinical examination and ECG was
unremarkable but an echocardiogram demon-
strated ‘unusual ventricular foreshortening’.
Subsequent cardiac magnetic resonance im-
aging demonstrated all four characteristics of a
rare primary cardiomyopathy. A truncated left
ventricle (Panels A and B), spherical remodelling,
and bulging of the inter-ventricular septum
towards the right ventricle (Panels B, D, and E).
RV apex formation with wrapping around of the
RV apex around the deficient left ventricular
apex (Panels A and B) and fatty replacement of
the LV apex (Panels D, E and H ). In this case,
apical fat pad and additional apical fatty infiltration
of the LV apex were clearly delineated by T1
mapping (Panel F) which to our knowledge
has not been applied in this pathology before.
Late gadolinium enhancement revealed mid-wall
hyper-enhancement in the mid-ventricular
septum (Panels D and E). Taken together these
findings were diagnostic of left ventricular apical
hypoplasia (LVAH) (Supplementary material
online, Video 1).
Left ventricular apical hypoplasia was first identified in 2004 and is postulated to be a congenital abnormality due to inadequate dilatation
of chambers during partitioning. This is the third case to identify mid-wall fibrosis in a case of LVAH. This finding has not consistently
been described, as a characteristic of LVAH suggesting the possible role of CMR in risk stratifying patients with this poorly understood
condition. Furthermore, this may provide evidence for an overlap with other inherited idiopathic cardiomyopathies of the DCM spectrum.
Patients usually present with mild, non-specific symptoms although arrhythmic presentations have been reported. Most respond well
to standard cardiac failure therapy.
Supplementary material is available at European Heart Journal online.
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2014. For permissions please email: journals.permissions@oup.com.
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